Home › Compare › GMDA vs NNN

GMDA vs NNN: Dividend Comparison 2026

GMDA yields 6116.21% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GMDA wins by $442825559222013.81M in total portfolio value
10 years
GMDA
GMDA
● Live price
6116.21%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$442825559222013.81M
Annual income
$429,026,802,483,037,700,000.00
Full GMDA calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — GMDA vs NNN

📍 GMDA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMDANNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMDA + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GMDA pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMDA
Annual income on $10K today (after 15% tax)
$519,877.68/yr
After 10yr DRIP, annual income (after tax)
$364,672,782,110,582,000,000.00/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, GMDA beats the other by $364,672,782,110,582,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMDA + NNN for your $10,000?

GMDA: 50%NNN: 50%
100% NNN50/50100% GMDA
Portfolio after 10yr
$221412779611006.91M
Annual income
$214,513,401,241,518,830,000.00/yr
Blended yield
96.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GMDA right now

GMDA
Analyst Ratings
7
Buy
1
Hold
Consensus: Buy
Altman Z
-12.9
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMDA buys
0
NNN buys
0
No recent congressional trades found for GMDA or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMDANNN
Forward yield6116.21% ✓5.68%
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$442825559222013.81M ✓$25.6K
Annual income after 10y$429,026,802,483,037,700,000.00 ✓$2,637.42
Total dividends collected$441897573176239.63M ✓$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: GMDA vs NNN ($10,000, DRIP)

YearGMDA PortfolioGMDA Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$622,321$611,620.80$10,737$617.02+$611.6K → GMDA
2$36,238,251$35,572,368.18$11,577$710.93+$36.23M → GMDA
3$1,974,670,479$1,935,895,550.07$12,538$822.59+$1974.66M → GMDA
4$100,701,235,006$98,588,337,593.13$13,645$956.06+$100701.22M → GMDA
5$4,806,495,889,234$4,698,745,567,778.20$14,925$1,116.51+$4806495.87M → GMDA
6$214,743,265,021,614$209,600,314,420,132.84$16,415$1,310.57+$214743265.01M → GMDA
7$8,981,610,447,341,976$8,751,835,153,768,850.00$18,158$1,546.77+$8981610447.32M → GMDA
8$351,707,912,645,944,000$342,097,589,467,288,100.00$20,213$1,836.20+$351707912645.92M → GMDA
9$12,896,034,335,491,684,000$12,519,706,868,960,524,000.00$22,649$2,193.37+$12896034335491.66M → GMDA
10$442,825,559,222,013,800,000$429,026,802,483,037,700,000.00$25,558$2,637.42+$442825559222013.81M → GMDA

GMDA vs NNN: Complete Analysis 2026

GMDA — Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Full GMDA Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this GMDA vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMDA vs SCHDGMDA vs JEPIGMDA vs OGMDA vs KOGMDA vs MAINGMDA vs ADCGMDA vs EPRTGMDA vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.